Study of isopropyl myristate microemulsion systems containing cyclodextrins to improve the solubility of 2 model hydrophobic drugs.
The objectives of this project were to evaluate the effect of alkanols and cyclodextrins on the phase behavior of an isopropyl myristate microemulsion system and to examine the solubility of model drugs. Triangular phase diagrams were developed for the microemulsion systems using the water titration method, and the solubility values of progesterone and indomethacin were determined using a conventional shake-flask method. The water assimilation capacities were determined to evaluate the effective microemulsion formation in different systems. The alkanols showed higher microemulsion formation rates at higher concentrations. A correlation between the carbon numbers of the alkanol and water assimilation capacity in the microemulsions studied was observed; isobutanol and isopentanol produced the best results. The addition of cyclodextrins showed no effect or had a negative effect on the microemulsion formation based on the type of cyclodextrin used. Isopropyl myristate-based microemulsion systems alone could increase the solubility values of progesterone and indomethacin up to 3300-fold and 500-fold, respectively, compared to those in water. However, the addition of cyclodextrins to the microemulsion systems did not show a synergistic effect in increasing the solubility values of the model drugs. In conclusion, microemulsion systems improve the solubility of progesterone and indomethacin. But the two types of cyclodextrins studied affected isopropyl myristate-based microemulsion systems negatively and did not improve the solubilization of 2 model drugs.
Nandi
Indranil
I
Geneva Pharmaceutical Technology Corp, Dayton, NJ 08810, USA.
Bari
Mohammad
M
Joshi
Hemant
H
D000438:Alcohols / Q000737:chemistry; D003505:Cyclodextrins / Q000737:chemistry*; D004655:Emulsions; D057927:Hydrophobic and Hydrophilic Interactions; D007213:Indomethacin / Q000008:administration & dosage / Q000737:chemistry*; D009226:Myristates / Q000737:chemistry*; D014677:Pharmaceutical Vehicles; D011374:Progesterone / Q000008:administration & dosage / Q000737:chemistry*; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry
D000438:Alcohols; D003505:Cyclodextrins; D004655:Emulsions; D009226:Myristates; D014677:Pharmaceutical Vehicles; D013501:Surface-Active Agents; C008205:isopropyl myristate; D011374:Progesterone; D007213:Indomethacin